Biotron Ltd
BIT
Company Profile
Business description
Biotron Ltd is a biotechnology company. It is engaged in the funding and management of intermediate and applied biotechnology research and development projects. Its antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. Geographically, it operates only in Australia through biotechnology segment.
Contact
66 Hunter Street
Level 2
SydneyNSW2000
AUST: +61 293003344
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
4
Stocks News & Analysis
stocks
10 best US growth stocks to buy for the long term
The stocks of these high-quality growth companies look undervalued today.
stocks
Higher fair value for overvalued ASX tech share
Underlying secular growth stronger than we thought.
stocks
Nvidia: Collaboration with Intel might bring some goodwill with the US
We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,102.10 | 11.70 | 0.13% |
| CAC 40 | 7,830.11 | 23.48 | -0.30% |
| DAX 40 | 23,527.05 | 112.36 | -0.48% |
| Dow JONES (US) | 46,338.97 | 23.70 | 0.05% |
| FTSE 100 | 9,226.68 | 10.01 | 0.11% |
| HKSE | 26,344.14 | 200.96 | -0.76% |
| NASDAQ | 22,736.37 | 104.89 | 0.46% |
| Nikkei 225 | 45,493.66 | 447.85 | 0.99% |
| NZX 50 Index | 13,141.54 | 90.12 | -0.68% |
| S&P 500 | 6,681.95 | 17.59 | 0.26% |
| S&P/ASX 200 | 8,810.90 | 11.40 | 0.13% |
| SSE Composite Index | 3,828.58 | 8.49 | 0.22% |